1 / 16

Yale SPORE in Skin Cancer

Yale SPORE in Skin Cancer. Directors: Ruth Halaban, PhD Mario Sznol, MD Robert Tigelaar, MD. Funded by: National Institutes of Health The Roslyn and Jeremy Meyer funds Yale Dermatology Department. Milstein Meyer Center for Melanoma Research. Jeremy Meyer and Roslyn Milstein Meyer

dempster
Download Presentation

Yale SPORE in Skin Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Yale SPORE in Skin Cancer Directors: Ruth Halaban, PhD Mario Sznol, MD Robert Tigelaar, MD Funded by: National Institutes of Health The Roslyn and Jeremy Meyer funds Yale Dermatology Department

  2. Milstein Meyer Center for Melanoma Research Jeremy Meyer and Roslyn Milstein Meyer “Couple with a Cause” Gift of $2 Million/year renewable for additional 4 years

  3. The SPORE Program Translation Research in Skin Cancer Melanomas Basal Cell Carcinoma

  4. The SPORE Program • Three cores that support SPORE activities • Four translational projects • Developmental Research Projects • Career Development Projects

  5. 4 Paid investigators 3 Patient advocates 2 1 Translational Research TeamSPORE Expansion 7 0 Roslyn Milstein Meyer Susan Cambria Robin Bessin Robert Heffernan 6 0 5 0 Number of Investigators 4 0 3 0 2 0 1 0 0 0 Y e a r 1 Y e a r 2 ( S u b m i s s i o n )

  6. Translational Research Team 1 Dermatology 2 YCCC/Oncology 3 Pathology 4 Surgery 5 Genetics 6 Immunobiology 7 Epidemiology 8 Chemical & Biomedical Engineering 9 Therapeutic Radiology 10 Laboratory Medicine and Genetics • Molecular, Cellular, and Developmental Biology • Cell Biology, New York University, NY

  7. “The Melanoma Landscape” Comprehensive understanding of: • Critical changes that drive melanomas • Immunobiology of melanomas • The causes for drug resistance • New targets for therapy, single and combination • Markers for prognosis and therapy

  8. SPORE Biospecimen Bank • Normal skin and cells • Tumors • Tumor cells • Blood from healthy individuals • Blood from patients Specimen Tracking and Annotation caTissue

  9. Specimens’ Collection in the Tissue Bank 700 600 500 Total Number of Specimens 400 300 200 100 0 Submission Year 1 Year 2 Current Year 2 1/2

  10. Serological Profiling of Melanoma Patients Marker A Marker B Concentration (ng/ml) Weeks of Treatment

  11. Global “Omics” Test • Genetic and epigenetic variations • Mutations • Gene expression • Kinases and signal transducers • MicroRNA

  12. Global Epigenetic Differences Between Normal and Malignant Cells Normal Melanoma Loss Gain

  13. Differences in Gene Expression Between Normal and Malignant Cells Melanoma Normal Gain Loss

  14. Interactions Between the SPORE and Clinicians • Help in testing for mutations in tumors for targeted therapy • For example: selection of patients to therapy with PLX4032 (Plexxikon Inc.) and Imatinib (Gleevec, Novartis Pharmaceuticals), activated BRAF and KIT inhibitors, respectively.

  15. Educational Activities • Invited speakers • Research in Progress meetings • Workshop for all SPOREs in Skin Cancer • Outreach with patient advocates

  16. Tumor excised Draw blood Comprehensive analyses: Which therapy? • Mutations • Activated targets • Drug response • Identify best therapy Results 1 0 0 Yes, this is the best for you 8 0 6 0 Surviving cells 4 0 2 0 0 None A B A+B DRUG Best-Case Scenario

More Related